Welcome to our dedicated page for Biolinerx SEC filings (Ticker: BLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLineRx Ltd. (BLRX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on NASDAQ and the Tel Aviv Stock Exchange. BioLineRx files annual reports on Form 20‑F and frequent current reports on Form 6‑K, which together document its financial performance, clinical progress and material corporate events.
Recent Form 6‑K filings referenced by the company include quarterly financial results for periods ended March 31, June 30 and September 30, 2025. These reports incorporate condensed consolidated interim financial statements and operating and financial reviews, giving detail on revenues from APHEXDA royalties, research and development expenses, general and administrative costs, and the company’s cash position and runway guidance.
Filings also cover transactional and strategic developments. For example, a September 29, 2025 Form 6‑K describes the joint venture agreement with Hemispherian AS and the asset transfer of GLIX1‑related intellectual property into a newly created company. The filing outlines ownership percentages, funding commitments, governance arrangements and rights related to additional assets in Hemispherian’s pipeline.
Other 6‑K submissions attach press releases on topics such as the USPTO Notice of Allowance for GLIX1 patents, as well as shareholder meeting results, including approvals of director elections, changes to authorized share capital, compensation policy updates and auditor appointments.
On Stock Titan, these BLRX filings are supplemented by AI‑powered summaries that explain the key points of each document in plain language. Users can quickly understand the implications of lengthy 20‑F and 6‑K reports, track changes in financial metrics over time, and identify disclosures related to clinical trials, licensing agreements, equity issuances and corporate governance. The page also links to information on insider and major shareholder activity when reported on applicable SEC forms.
BioLineRx Ltd. director Sandra Panem filed an initial ownership report showing multiple employee stock options to buy Ordinary Shares. The options cover blocks such as 199,800 shares at an exercise price of $0.356 and 1,080,000 shares at $0.085, with expirations between 2026 and 2034.
Footnotes state that earlier grants from 2016 through 2024 are fully vested, while an October 1, 2024 grant left 856,200 options vested at appointment and 1,198,800 options scheduled to vest in seven equal quarterly installments, subject to her continued service.
BioLineRx Ltd. director Raphael Hofstein filed an initial ownership report showing he holds several employee stock options over the company’s ordinary shares. This Form 3 does not report new purchases or sales, but lists option grants previously awarded under the company’s 2003 Amended and Restated Share Incentive Plan.
The disclosed positions include options exercisable at prices such as $0.8370, $0.9200, and as low as $0.0520 per share, with expiration dates ranging from July 2026 to August 2034. Footnotes state that most grants are already fully vested, while a large grant covering 2,055,000 underlying shares at $0.0520 has 856,200 options vested and 1,198,800 scheduled to vest in seven equal quarterly installments, contingent on his continued service.
BioLineRx Ltd. director Dar Rami reported initial holdings of employee stock options over Ordinary Shares. The Form 3 shows several option grants with exercise prices between $0.052 and $0.085, expiring between 2032 and 2034, granted under the 2003 Amended and Restated Share Incentive Plan.
One grant over 2,055,000 underlying shares at an exercise price of $0.052 includes 856,200 options vested as of the appointment date, with the remaining 1,198,800 vesting in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. director Molcho Avraham filed an initial ownership report showing a portfolio of employee stock options to acquire Ordinary Shares. The filing lists multiple fully vested grants made between July 2016 and July 2024 under the 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.920 per share and expirations between 2026 and 2034. One large grant covers 2,055,000 underlying shares at an exercise price of $0.052 per share, expiring in 2034, of which 856,200 options were vested on the October 1, 2024 grant date and the remaining 1,198,800 options vest in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. director Cohen Gal Avraham filed an initial ownership report detailing employee stock options over 2,055,000 underlying ordinary shares. These options carry an exercise price of $0.052 per share and expire on August 14, 2034.
The options were granted on October 1, 2024 under the company’s 2003 Amended and Restated Share Incentive Plan. As of the grant date, 856,200 options were vested, with the remaining 1,198,800 scheduled to vest in seven equal quarterly installments, subject to continued service. The filing reflects holdings only and does not report any purchases or sales.
BioLineRx Ltd. director Aharon Schwartz filed an initial ownership report showing direct holdings of 3,705,000 Ordinary Shares. He also holds multiple fully vested and time-vested employee stock options under the company’s 2003 Amended and Restated Share Incentive Plan, with exercise prices ranging from $0.052 to $0.92 per share and expirations extending through 2034. A large October 2024 grant covers 2,055,000 underlying Ordinary Shares, of which 856,200 were vested at appointment and the remaining 1,198,800 are scheduled to vest in seven equal quarterly installments, subject to continued service.
BioLineRx Ltd. filed an Amendment No. 1 to its Form 20-F for the fiscal year ended December 31, 2025. The amendment is limited to correcting the date referenced in the consent of its independent auditor, Kesselman & Kesselman, a member firm of PwC, filed as Exhibit 15.1.
Updated CEO and CFO certifications under Sections 302 and 906 of the Sarbanes-Oxley Act are included as new exhibits, as required for amendments. All other disclosures in the original annual report remain unchanged, and the amendment does not update events after the original filing.
BioLineRx Ltd. Chief Executive Officer Philip A. Serlin filed an initial ownership report detailing his equity position. He directly holds 5,131,800 Ordinary Shares and a series of employee stock options over additional Ordinary Shares with exercise prices ranging from $0.2640 down to $0.0450, expiring between 2026 and 2033. Several option grants are fully vested, while the most recent grant includes options that will vest in quarterly installments, subject to his continued service.
BioLineRx Ltd. has begun a first‑in‑human Phase 1/2a study of GLIX1, an oral, first‑in‑class TET2 activator, for recurrent and progressive glioblastoma and other high‑grade glioma. GLIX1 aims to selectively disrupt DNA damage repair in cancer cells while sparing healthy tissue.
The Phase 1 portion is expected to enroll up to 30 patients to determine a maximum tolerated or recommended dose based on safety, pharmacokinetics/pharmacodynamics and early efficacy, with initial data anticipated in the first half of 2027. The Phase 2a expansion will test GLIX1 in multiple tumor cohorts and combinations, including with standard treatments such as PARP inhibitors.
The trial is led by world‑recognized GBM investigators at NYU Langone Health, Northwestern University and Moffitt Cancer Center, under a collaboration with Hemispherian AS. BioLineRx also highlights its approved product APHEXDA for stem cell mobilization in multiple myeloma and an ongoing Phase 2b study of motixafortide in metastatic pancreatic cancer.
BioLineRx Ltd. reported audited 2025 results and highlighted progress in its oncology and rare disease pipeline. Total revenues fell to $1,180 thousand in 2025 from $28,940 thousand in 2024, reflecting a sharp decline in license and product revenues. The loss attributable to owners narrowed to $1,175 thousand, versus $9,221 thousand in 2024, as operating loss decreased and non‑operating income supported results.
At December 31, 2025, cash and cash equivalents were $3,250 thousand and short-term deposits were $17,626 thousand, with total assets of $40,905 thousand and total equity of $23,345 thousand. Management expects to initiate a Phase 1/2a clinical trial of GLIX1 in glioblastoma by the end of March 2026 and continues a Phase 2b motixafortide trial in metastatic pancreatic cancer, alongside commercialization of APHEXDA for stem cell mobilization in multiple myeloma.